Abstract 68P
Background
Luminal A (ER+/ HER2-low) is the most common breast cancer subtype and hormonal therapy is the preferred first-line treatment. However, most patients (>50%) develop resistance, leading to disease recurrence and limited clinical benefit, even with the addition of a combination regimen. Therefore, treatment optimization is required urgently. Furthermore, studies have indicated that the tumours with low HER2 and ER levels evade ER blockade via the upregulation of EGFR/HER2 signalling. Therefore, this study will aim to assess the effects of anti-HER2 in combination with hormone treatment in ER+/HER2-low breast cancer.
Methods
A panel of patient-derived organoids ( n=31) was successfully established and characterized using immunohistochemical and confocal imaging. Through the drug sensitivity test, the drug combination efficacy of the anti-HER2 drug (neratinib), hormone treatment (fulvestrant), and CDK4/6 inhibitor (palbociclib) was tested in HER2-low breast cancer patient-derived organoids. The underlying molecular mechanisms were investigated using immunofluorescence, western blot analysis, immunohistochemical staining, and cell cycle analysis.
Results
We found that neratinib combined with palbociclib and or fulvestrant showed better efficacy than palbociclib and fulvestrant combination in HER2-low breast cancer, resulting in the deactivation of HER2-EGFR signalling pathway, decreased transcriptional activation of ER and cycle proteins. Furthermore, the dual or triple combination of neratinib, palbociclib, and fulvestrant could decrease the nuclear translocation of ER. This may be the underlying mechanism by which the addition of palbociclib and/or fulvestrant to neratinib was more beneficial than the combination of palbociclib plus fulvestrant.
Conclusions
Our study provides the rationale for combining neratinib with fulvestrant and or palbociclib for the treatment of ER+/HER2-low breast cancer and indicates that the dual or triple combination treatment may be a better strategy to overcome resistance to hormone treatment. Moreover, future translational research will investigate the potential biomarkers indicating the responsiveness to the treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Puma biotechnology.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract